Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rishi Roy

Vascular Surgery Ocean Springs, MS Medical Doctor

NPI 1215249016 CMS profile 397657

3603 Bienville Blvd Ste 103, Ocean Springs, MS 39564

Open in the dashboard

General payments

$75,101

806 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rishi Roy of Ocean Springs, MS is reported in the CMS Open Payments database as having received $75,101 across 806 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,444 57
2024 General $11,352 102
2023 General $21,801 153
2022 General $17,503 166
2021 General $7,485 108
2020 General $6,404 106
2019 General $7,114 114

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rishi Roy
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Rishi Roy were reported at $3,444. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Rishi Roy Vascular Surgery median Middle half National median
2019 $7,114 $796 $226–$2,363 $163
2020 $6,404 $348 $118–$1,110 $114
2021 $7,485 $471 $158–$1,421 $132
2022 $17,503 $725 $222–$2,183 $149
2023 $21,801 $836 $257–$2,440 $160
2024 $11,352 $909 $252–$2,619 $164
2025 $3,444 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AngioDynamics, Inc. $28,960 48 payments
  2. W. L. Gore & Associates, Inc. $15,559 312 payments
  3. Medtronic, Inc. $13,359 107 payments
  4. Silk Road Medical, Inc. $2,633 23 payments
  5. Inari Medical, Inc. $1,916 97 payments
  6. Cardiovascular Systems Inc. $1,858 14 payments
  7. Abbott Laboratories $1,231 33 payments
  8. Medtronic Vascular, Inc. $1,148 25 payments
  9. Philips Electronics North America Corporation $1,147 18 payments
  10. Bolton Medical Inc $1,069 15 payments
  11. Other $6,220 114 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $38,197 779 payments
  2. Long term medical supply or device loan $24,875 2 payments
  3. Travel and Lodging $11,982 24 payments
  4. Education $47 1 payment
Products named General payments · program years 2019–2025
  1. Auryon Laser System 100-120 Vac Et $26,716 6 payments
  2. HawkOne $7,700 21 payments
  3. AURYON LASER SYSTEM 100-120 VAC Pad $2,194 38 payments
  4. GORE VIABAHN VBX Balloon Expandable Endo $2,183 34 payments
  5. ENROUTE 0.014 Guidewire $1,772 12 payments
  6. ENROUTE Transcarotid Stent System $1,772 12 payments
  7. ENROUTE Transcarotid Neuroprotection System $1,772 12 payments
  8. ENHANCE Transcarotid Peripheral Access Kit $1,772 12 payments
  9. Peripheral Orbital Atherectomy System $1,616 10 payments
  10. ENDURANT IIS $1,565 23 payments
  11. Other $36,960 809 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

229

Median for Vascular Surgery: 122

Drug cost

$89,533

Median for Vascular Surgery: $14,135

Branded share of claims

94.8%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 114 $74,272
Eliquis Apixaban Brand 20 $14,685
Clopidogrel Clopidogrel Bisulfate Brand 83 $548
Tramadol Hcl Generic 12 $27

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$190,797

Medicare's payments for the services billed

Medicare patients

186

Average age 75

Services billed

467

93 women, 93 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 64%
Ischemic heart disease 57%
Diabetes 52%
Chronic kidney disease 42%
Heart failure 40%
Atrial fibrillation 30%
Depression 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

806 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record